Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
"David's contributions to Allogene were immeasurable. His wisdom, guidance, and steadfast commitment to revolutionizing cancer treatment have left an indelible mark on Allogene, the field of CAR T, and the world of science," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "Our deepest sympathies go out to the Bonderman family and all of those who were fortunate to know him. We join them in honoring a remarkable man whose contributions will continue to save lives and bring transformative treatments to those in need, leaving an enduring legacy in the world of human health."SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today acknowledged the passing of founding board member, David Bonderman. David died at the age of 82, surrounded by his family.
加利福尼亞州南舊金山，2024年12月12日（環球新聞）-- Allogene Therapeutics，Inc.（納斯達克：ALLO），一家處於臨床階段的生物技術公司，正在開拓開發用於癌症和自身免疫疾病的同種異體CAR t（AlloCAR T）產品，今天確認創始董事會成員大衛·邦德曼（David Bonderman）去世。大衛在82歲時去世，身邊陪伴着家人。
"We are deeply saddened by the passing of our founding board member and dear friend," said Arie Belldegrun, M.D., Executive Chairman and Co-Founder of Allogene. "David was more than a board member – he was a champion of innovation, a trusted mentor, and an enduring source of inspiration to all of us. He was also an unwavering believer in the groundbreaking potential of CAR T therapy. Long before Allogene was founded, David recognized the promise of this innovative approach, becoming one of the earliest advocates and supporters of Kite Pharma. His passion and dedication only deepened over time as he helped to guide the establishment and evolution of Allogene. Words cannot express how much he will be missed."
「我們對我們創始董事會成員和親愛的朋友的去世感到深感悲痛，」Allogene的執行主席和聯合創始人阿里·貝爾德格倫（Arie Belldegrun）博士說。「大衛不僅僅是一位董事會成員——他還是創新的倡導者，一個值得信賴的導師，以及我們所有人持久的靈感來源。他也是對CAR t療法突破性潛力的堅定信仰者。在Allogene成立之前，大衛就意識到了這種創新方法的前景，成爲Kite Pharma最早的倡導者和支持者之一。隨着他幫助指導Allogene的建立和發展，他的激情和奉獻精神愈加深厚。言語無法表達他會被多麼懷念。」
A steadfast advocate for CAR T-cell therapy, David's contributions to Allogene are immeasurable. He served on Allogene's Board of Directors since its founding in 2018, taking on the role of Lead Independent Director. In this capacity, he championed innovation, provided trusted mentorship, and served as a constant source of inspiration to all who worked alongside him.
作爲CAR t細胞療法的堅定擁護者，大衛對Allogene的貢獻是不可估量的。自2018年創立以來，他一直擔任Allogene董事會成員，並擔任首席獨立董事。在此期間，他倡導創新，提供值得信賴的指導，併成爲所有與他共事者持續的靈感來源。
"David's contributions to Allogene were immeasurable. His wisdom, guidance, and steadfast commitment to revolutionizing cancer treatment have left an indelible mark on Allogene, the field of CAR T, and the world of science," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "Our deepest sympathies go out to the Bonderman family and all of those who were fortunate to know him. We join them in honoring a remarkable man whose contributions will continue to save lives and bring transformative treatments to those in need, leaving an enduring legacy in the world of human health."
「大衛對Allogene的貢獻是不可估量的。他的智慧、指導和對徹底改變癌症治療的堅定承諾在Allogene、CAR t領域和科學界留下了不可磨滅的印記，」Allogene的總裁、首席執行官和聯合創始人大衛·張（David Chang）博士說。「我們最深切的慰問送給邦德曼家族以及所有有幸認識他的人。我們與他們一道，向這位卓越的人的貢獻致敬，他的貢獻將繼續拯救生命，併爲那些有需要的人帶來變革性治療，給盈健醫療的世界留下持久的遺產。」
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of "off-the-shelf" CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit , and follow Allogene Therapeutics on X and LinkedIn.
關於Allogene Therapeutics
Allogene Therapeutics總部位於南舊金山，是一家臨床階段的生物技術公司，正在開拓開發用於癌症和自身免疫疾病的異源嵌合抗原受體T細胞（AlloCAR T）產品。由一支在電芯療法方面擁有豐富經驗的管理團隊領導，Allogene正在開發一系列「即用型」CAR T細胞產品候選者，旨在爲更多患者提供更可靠、按需提供的電芯療法，並且能以更大規模交付。如需更多信息，請訪問，關注Allogene Therapeutics的X和LinkedIn。
AlloCAR T is a trademark of Allogene Therapeutics, Inc.
AlloCAR T是Allogene Therapeutics, Inc.的商標。
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
Allogene媒體/投資者聯繫方式：
克莉絲汀·卡西亞諾
執行副總裁，首席企業事務及品牌策略官
Christine.Cassiano@allogene.com
譯文內容由第三人軟體翻譯。
